Ever since facing its initial setback with the FDA half a decade ago, Lexicon Ph...
For patients with recurrent glioblastoma, the chimeric antigen receptor T-cell (...
Since its initial rejection by the FDA approximately five years ago, Lexicon Pha...
The pharmaceutical giant Pfizer revealed positive results from a late-stage stud...
HiLabs, a health technology enterprise powered by artificial intelligence, is de...
Eli Lilly’s recent breakthrough in eczema treatment represents a stride in addre...
In its pursuit of Regeneron and Sanofi’s Dupixent in the treatment of prurigo no...
Iovance Biotherapeutics has had a partial clinical hold imposed by the FDA. This...
Merck KGaA has been brought on board by the Massachusetts biotechnology company ...
In a recent unveiling at the 2024 Conference on Retroviruses and Opportunistic I...
NovAliX, a specialized contract research company that is committed to facilitati...
Bispecific T-cell engagers are gaining prominence in oncology, yet this hasn’t d...
Agiliti is withdrawing from the public market, a move that comes less than three...
In recent developments, the FDA has greenlighted one antibiotic combination ther...
AstraZeneca and FibroGen have concluded their collaboration on the oral anemia m...
The Laboratorios Farmacéuticos Rovi and Moderna partnership has recently achieve...
